Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)-a multicentre, double-blind, randomised, placebo-controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Mechanical respiratory support in cardiogenic shock: reply

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Pulmonary artery pulsatility index: physiological basis and clinical application

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Reproducibility of in-hospital worsening heart failure event adjudication in the RELAX-AHF-EU trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Favorable five-year outcomes for heart failure diagnosed in younger patients without severe comorbidity

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Associations between blood cultures after surgery for colorectal cancer and long-term oncological outcomes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Evaluation of computed tomography myocardial perfusion in women with angina and no obstructive coronary artery disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Catheter ablation for atrial fibrillation is associated with lower incidence of heart failure and death

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: To determine the effect of the glucagon-like peptide-1 analogue liraglutide on left ventricular function in chronic heart failure patients with and without type 2 diabetes.

METHODS AND RESULTS: LIVE was an investigator-initiated, randomised, double-blinded, placebo-controlled multicentre trial. Patients (n = 241) with reduced left ventricular ejection fraction (LVEF ≤45%) were recruited (February 2012 to August 2015). Patients were clinically stable and on optimal heart failure treatment. Intervention was liraglutide 1.8 mg once daily or matching placebo for 24 weeks. The LVEF was similar at baseline in the liraglutide and the placebo group (33.7 ± 7.6% vs. 35.4 ± 9.4%). Change in LVEF did not differ between the liraglutide and the placebo group; mean difference (95% confidence interval) was -0.8% (-2.1, 0.5; P = 0.24). Heart rate increased with liraglutide [mean difference: 7 b.p.m. (5, 9), P < 0.0001]. Serious cardiac events were seen in 12 (10%) patients treated with liraglutide compared with 3 (3%) patients in the placebo group (P = 0.04).

CONCLUSION: Liraglutide did not affect left ventricular systolic function compared with placebo in stable chronic heart failure patients with and without diabetes. Treatment with liraglutide was associated with an increase in heart rate and more serious cardiac adverse events, and this raises some concern with respect to the use of liraglutide in patients with chronic heart failure and reduced left ventricular function. More data on the safety of liraglutide in different subgroups of heart failure patients are needed.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Heart Failure
Vol/bind19
Udgave nummer1
Sider (fra-til)69-77
ISSN1388-9842
DOI
StatusUdgivet - 2017

ID: 49154599